曲妥珠-话题@MedSci

#曲妥珠#

132篇内容 | 3725人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1648170, encodeId=1fcd16481e0a9, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, objectType=article, longId=199921, objectId=e4ad199921fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4ad199921fd, replyNumber=0, likeNumber=137, createdTime=2021-07-30, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4ad199921fd, moduleTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4ad199921fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648167, encodeId=36be164816e91, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Gastric Cancer：波齐替尼联合紫杉醇和曲妥珠单抗治疗HER2阳性晚期胃癌患者的效果, objectType=article, longId=198092, objectId=8f48198092eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f48198092eb, replyNumber=0, likeNumber=120, createdTime=2021-04-10, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f48198092eb, moduleTitle=Gastric Cancer：波齐替尼联合紫杉醇和曲妥珠单抗治疗HER2阳性晚期胃癌患者的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f48198092eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648169, encodeId=9b8f1648169af, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NMPA批准中国曲妥珠单抗生物仿制药, objectType=article, longId=199752, objectId=d6c5199e5254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6c5199e5254, replyNumber=0, likeNumber=95, createdTime=2021-03-18, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6c5199e5254, moduleTitle=NMPA批准中国曲妥珠单抗生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6c5199e5254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648160, encodeId=1937164816016, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, objectType=article, longId=193392, objectId=a9c11933925d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9c11933925d, replyNumber=0, likeNumber=0, createdTime=2020-07-31, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9c11933925d, moduleTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9c11933925d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648152, encodeId=cad4164815250, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=AZ/Daiichi的乳腺癌曲妥珠抗体偶联药物ADC获得美国优先审查, objectType=article, longId=181535, objectId=7549181535e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7549181535e0, replyNumber=0, likeNumber=107, createdTime=2020-09-04, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7549181535e0, moduleTitle=AZ/Daiichi的乳腺癌曲妥珠抗体偶联药物ADC获得美国优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7549181535e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648162, encodeId=c621164816246, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=中国生物仿制药出海：曲妥珠单抗生物仿制药HLX02获CHMP正面评价, objectType=article, longId=195153, objectId=438319515359, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=438319515359, replyNumber=0, likeNumber=55, createdTime=2021-02-09, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=438319515359, moduleTitle=中国生物仿制药出海：曲妥珠单抗生物仿制药HLX02获CHMP正面评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=438319515359)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648157, encodeId=bb9a164815ef3, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NEJM：曲妥珠单抗-美坦新偶联物二线治疗HER-2转移性乳腺癌, objectType=article, longId=187963, objectId=d19718e96350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d19718e96350, replyNumber=0, likeNumber=52, createdTime=2020-06-29, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d19718e96350, moduleTitle=NEJM：曲妥珠单抗-美坦新偶联物二线治疗HER-2转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d19718e96350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648164, encodeId=81ab16481648a, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NEJM：恩美曲妥珠单抗治疗早期乳腺癌的效果显著, objectType=article, longId=195892, objectId=9cbf195892f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cbf195892f1, replyNumber=0, likeNumber=79, createdTime=2020-07-08, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cbf195892f1, moduleTitle=NEJM：恩美曲妥珠单抗治疗早期乳腺癌的效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9cbf195892f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648158, encodeId=76501648158d2, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=J Clin Oncol：曲妥珠单抗治疗HER2低表达乳腺癌的疗效和安全性, objectType=article, longId=188283, objectId=be8d18828340, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be8d18828340, replyNumber=0, likeNumber=67, createdTime=2020-07-02, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be8d18828340, moduleTitle=J Clin Oncol：曲妥珠单抗治疗HER2低表达乳腺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be8d18828340)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648153, encodeId=3ba21648153c9, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, objectType=article, longId=183554, objectId=f33d18355468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f33d18355468, replyNumber=0, likeNumber=91, createdTime=2020-09-27, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f33d18355468, moduleTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f33d18355468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648155, encodeId=09c11648155cb, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, objectType=article, longId=184670, objectId=4c281846e069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c281846e069, replyNumber=0, likeNumber=71, createdTime=2020-09-16, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c281846e069, moduleTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c281846e069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648146, encodeId=da6f164814618, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Circulation：曲妥珠单抗心毒性的细胞机制, objectType=article, longId=167137, objectId=55e016e137f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55e016e137f6, replyNumber=0, likeNumber=73, createdTime=2019-06-08, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55e016e137f6, moduleTitle=Circulation：曲妥珠单抗心毒性的细胞机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55e016e137f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648151, encodeId=90f616481519b, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果, objectType=article, longId=179522, objectId=8c931e952273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c931e952273, replyNumber=0, likeNumber=76, createdTime=2019-12-23, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c931e952273, moduleTitle=Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c931e952273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648143, encodeId=f1511648143ec, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet oncol：曲妥珠单抗deruxtecan用于HER2阳性的胃或胃食管交界癌的疗效和安全性, objectType=article, longId=165380, objectId=4e2c165380ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2c165380ae, replyNumber=0, likeNumber=62, createdTime=2020-01-25, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2c165380ae, moduleTitle=Lancet oncol：曲妥珠单抗deruxtecan用于HER2阳性的胃或胃食管交界癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2c165380ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648154, encodeId=06791648154e1, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=曲妥珠单抗耐药后更换不同作用机制的抗HER2药物，给患者带来更多获益, objectType=article, longId=183908, objectId=8ceb183908d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ceb183908d4, replyNumber=0, likeNumber=75, createdTime=2020-04-21, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ceb183908d4, moduleTitle=曲妥珠单抗耐药后更换不同作用机制的抗HER2药物，给患者带来更多获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ceb183908d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648147, encodeId=3ebb164814ecb, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, objectType=article, longId=167495, objectId=7c2016e4958b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c2016e4958b, replyNumber=0, likeNumber=75, createdTime=2019-11-20, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c2016e4958b, moduleTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c2016e4958b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648156, encodeId=e2d0164815615, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, objectType=article, longId=184671, objectId=d1461846e154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1461846e154, replyNumber=0, likeNumber=70, createdTime=2020-05-18, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1461846e154, moduleTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1461846e154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648150, encodeId=a3ce1648150f0, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet：早期HER2阳性乳腺癌患者可采用6个月曲妥珠单抗治疗方案, objectType=article, longId=174435, objectId=e0b31e443588, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0b31e443588, replyNumber=0, likeNumber=84, createdTime=2020-01-27, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0b31e443588, moduleTitle=Lancet：早期HER2阳性乳腺癌患者可采用6个月曲妥珠单抗治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0b31e443588)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648149, encodeId=9413164814975, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet：曲妥珠单抗辅助治疗乳腺癌，持续6个月还是12个月？, objectType=article, longId=167836, objectId=4c1016e836fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c1016e836fd, replyNumber=0, likeNumber=0, createdTime=2019-12-29, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c1016e836fd, moduleTitle=Lancet：曲妥珠单抗辅助治疗乳腺癌，持续6个月还是12个月？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c1016e836fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648142, encodeId=15ac16481426b, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet Oncol：帕妥珠单抗联合曲妥珠单抗治疗HER2阳性结肠癌, objectType=article, longId=162238, objectId=18f71622382c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18f71622382c, replyNumber=0, likeNumber=90, createdTime=2019-09-01, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18f71622382c, moduleTitle=Lancet Oncol：帕妥珠单抗联合曲妥珠单抗治疗HER2阳性结肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18f71622382c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

曲妥珠

2020-05-29

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究

2021-07-30

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Gastric Cancer：波齐替尼联合紫杉醇和曲妥珠单抗治疗HER2阳性晚期胃癌患者的效果

2021-04-10

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NMPA批准中国曲妥珠单抗生物仿制药

2021-03-18

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期

2020-07-31

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

AZ/Daiichi的乳腺癌曲妥珠抗体偶联药物ADC获得美国优先审查

2020-09-04

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

中国生物仿制药出海：曲妥珠单抗生物仿制药HLX02获CHMP正面评价

2021-02-09

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NEJM：曲妥珠单抗-美坦新偶联物二线治疗HER-2转移性乳腺癌

2020-06-29

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NEJM：恩美曲妥珠单抗治疗早期乳腺癌的效果显著

2020-07-08

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

J Clin Oncol：曲妥珠单抗治疗HER2低表达乳腺癌的疗效和安全性

2020-07-02

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点

2020-09-27

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌

2020-09-16

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Circulation：曲妥珠单抗心毒性的细胞机制

2019-06-08

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果

2019-12-23

zhouqu_8 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet oncol：曲妥珠单抗deruxtecan用于HER2阳性的胃或胃食管交界癌的疗效和安全性

2020-01-25

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

曲妥珠单抗耐药后更换不同作用机制的抗HER2药物，给患者带来更多获益

2020-04-21

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请

2019-11-20

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗

2020-05-18

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet：早期HER2阳性乳腺癌患者可采用6个月曲妥珠单抗治疗方案

2020-01-27

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet：曲妥珠单抗辅助治疗乳腺癌，持续6个月还是12个月？

2019-12-29

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet Oncol：帕妥珠单抗联合曲妥珠单抗治疗HER2阳性结肠癌

2019-09-01

科室
- - 订阅+
  - 更多科室
工具
服务